Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR1248)
Drug Name
Pazopanib
Synonyms
Pazopanib; Pazopanib (GW-786034); 444731-52-6; 5-((4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide; 5-(4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide; 5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide; 790713-33-6; 7RN5DR86CK; CHEBI:71219; DSSTox_CID_28659; DSSTox_GSID_48733; DSSTox_RID_82929; GW 78603; GW 786034; GW-786034; GW786034; MFCD11616589; NCGC00188865-01; UNII-7RN5DR86CK
Indication Renal cell carcinoma [ICD11: 2C90] Approved [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 437.5 Topological Polar Surface Area 127
Heavy Atom Count 31 Rotatable Bond Count 5
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 8
Cross-matching ID
PubChem CID
10113978
ChEBI ID
CHEBI:71219
CAS Number
444731-52-6
Formula
C21H23N7O2S
Canonical SMILES
CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
InChI
1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)
InChIKey
CUIHSIWYWATEQL-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Pazopanib hydrochloride DM001182
11525740
Oxidation - Hydroxylation; N-Demethylation 1 [3] , [2] , [4]
Pazopanib metabolite M1 DM001183
72942037
Oxidation - Hydroxylation 1 [4]
Pazopanib metabolite M2 DM001184
72942038
Oxidation - Hydroxylation 1 [4]
Pazopanib metabolite M3 DM001185
68319455
Oxidation - N-Demethylation 1 [4]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR001948 Pazopanib Pazopanib hydrochloride Oxidation - Hydroxylation; N-Demethylation CYP3A4 ... [3], [2], [4]
MR001949 Pazopanib Pazopanib metabolite M1 Oxidation - Hydroxylation Unclear [4]
MR001950 Pazopanib Pazopanib metabolite M2 Oxidation - Hydroxylation Unclear [4]
MR001951 Pazopanib Pazopanib metabolite M3 Oxidation - N-Demethylation Unclear [4]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 1A2 (CYP1A2) DME0003 Homo sapiens
CP1A2_HUMAN
1.14.14.1
[2]
Cytochrome P450 2C8 (CYP2C8) DME0018 Homo sapiens
CP2C8_HUMAN
1.14.14.1
[2]
Cytochrome P450 2D6 (CYP2D6) DME0009 Homo sapiens
CP2D6_HUMAN
1.14.14.1
[3]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[2]
References
1 Pazopanib was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35.
3 Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011 Mar 5;71(4):443-54.
4 Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer Xenobiotica. 2013 May;43(5):443-53. doi: 10.3109/00498254.2012.734642.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.